Publications by authors named "J O Boles"

Innovations in medicine have allowed children with cancer to attend school more frequently by increasing survival rates and improving access to outpatient therapies. Children with cancer still miss a significant proportion of school attendance and participation during treatment, thereby disrupting their educational experiences. "Monkey in My Chair" is a program in the United States that connects ill children with their schoolmates during illness-related absences to support their social relationships and eventual school re-entry into the school environment.

View Article and Find Full Text PDF

Background/objectives: Cattle-feeding systems may have health implications for consumers of beef products. Organic grass-fed (GRA) and conventional (CON) cattle-feeding systems may result in beef products with differing metabolite profiles and therefore could impact the postprandial metabolomic response of consumers. This study aims to measure whole beef metabolomics and postprandial metabolomic response of consumers between GRA and CON beef to elucidate potential health implications.

View Article and Find Full Text PDF

Background: Inflammation is a central process of many neurological diseases, and a growing number of studies suggest that non-brain-resident immune cells may contribute to this neuroinflammation. However, the unique contributions of specific immune cell subsets to neuroinflammation are presently unknown, and it is unclear how communication between brain-resident and non-resident immune cells underlies peripheral immune cell involvement in neuroinflammation.

Methods: In this study, we employed the well-established model of lipopolysaccharide (LPS)-induced neuroinflammation and captured brain-resident and non-resident immune cells from the brain and its vasculature by magnetically enriching cell suspensions from the non-perfused brain for CD45 + cells.

View Article and Find Full Text PDF
Article Synopsis
  • FOLFIRI, a treatment for metastatic colorectal cancer, was tested using a pharmacogenomic strategy to tailor irinotecan doses based on UGT1A1 genotypes to see if it could improve progression-free survival (PFS).
  • In a study with 100 participants, results showed a median PFS of 12.5 months, which was shorter than expected, with variations in PFS based on genotype.
  • Although a tailored irinotecan strategy showed modest improvements in PFS for certain genotypes, it did not significantly change overall treatment outcomes and shouldn't replace current standard practices for first-line treatment.
View Article and Find Full Text PDF